阿托伐他汀联合肠内营养治疗老年非酒精性脂肪肝伴代谢综合征的临床研究

Abstract
Figure/Table
References (23)
Related Citation (15)

Download: PDF (636 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the clinical effect of Atorvastatin combined with enteral nutrition in the treatment of senile non-alcoholic fatty liver with metabolic syndrome. Methods From January 2017 to May 2018, 83 elderly patients with non-alcoholic fatty liver disease associated with metabolic syndrome admitted to Xi′an Central Hospital Affiliated to Xi′an Jiaotong University were selected as research objects. Patients were randomly divided into the control group (n = 41) and the study group (n = 42) according to the random number table method. The control group was treated with enteral nutrition, and the study group was treated with Atorvastatin on this basis. The clinical efficacy of the two groups after treatment, the nutritional indexes before and after treatment, and the levels of inflammatory factors including interleukin-6 (IL-6), tumor necrosis factor alpha (TNF-α), and high-sensitivity C-reactive protein (hs-CRP) were compared between the two groups. Results The total clinical effective rate of the study group was significantly higher than that of the control group (P ＜ 0.05). IL-6, TNF-α and hs-CRP of the two groups before treatment showed no significant difference (P ＞ 0.05), while IL-6, TNF-α and hs-CRP of the two groups after treatment were lower than before treatment, and the study group were significantly lower than the control group (P ＜ 0.05). Body mass index (BMI), triceps brachii musculocutaneous fold thickness (TSF) and waist-to-hip ratio (WHR) of the two groups before treatment showed no statistically significant difference (P ＞ 0.05). After treatment, BMI and TSF of the two groups both decreased, and BMI of the study group was lower than that of the control group (P ＜ 0.05). TSF and WHR were compared between the two groups after treatment, and the difference was not statistically significant (P ＞ 0.05). The incidence of adverse reactions in the study group was significantly lower than that in the control group (P ＜ 0.05). Conclusion Atorvastatin combined with enteral nutrition in the treatment of senile non-alcoholic fatty liver with metabolic syndrome has definite effect, can significantly improve the nutritional status of patients, reduce the inflammatory response of patients, and has certain clinical application value.

Key words： Atorvastatin Enteral nutrition Elderly Nonalcoholic fatty liver Metabolic syndrome Clinical study

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	MIAO Yanxia1 WANG Fang2 QIAO Liangmei1 LIU Yixin1 LYV Yangmei1

Cite this article:

MIAO Yanxia1 WANG Fang2 QIAO Liangmei1 LIU Yixin1 LYV Yangmei1. Clinical study of Atorvastatin combined with enteral nutrition in the treatment of senile non-alcoholic fatty liver with metabolic syndrome[J]. 中国医药导报, 2019, 16(10): 80-83.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2019/V16/I10/80

[1] Alkhouri N，Poordad F，Lawitz E. Management of nonalcoholic fatty liver disease：Lessons learned from type 2 diabetes [J]. Hepatol Commun，2018，2（7）：778-785.
[2] 武红琴，阮祥燕，卢永军，等.多囊卵巢综合征患者合并代谢综合征的患病率和预测指标[J].首都医科大学学报，2015，36（4）：553-558.
[3] Zhao ZY，Liu D，Cao WJ，et al. Association between IgG N-glycans and Nonalcoholic Fatty Liver Disease in Han Chinese [J]. Biomed Environ Sci，2018，31（6）：454-458.
[4] Ronis MJ，Baumgardner JN，Marecki JC，et al. Dietary fat source alters hepatic gene expression profile and determines the type of liver pathology in rats overfed via total enteral nutrition [J]. Physiol Genomics，2012，44（22）：1073-1089.
[5] 许绍忠，李冬青，王希柱，等.阿托伐他汀钙对代谢综合征患者颈动脉内中膜厚度及其他相关指标的影响[J].中国药房，2015，26（21）：2904-2905，2906.
[6] 中华医学会肝病学分会脂肪肝和酒精性肝病学组.非酒精性脂肪性肝病诊疗指南[J].中华内科杂志，2007，19（1）：1-3.
[7] 中国成人血脂异常防治指南制订联合委员会.中国成人血脂异常防治指南[J].中华心血管病杂志，2007，35（5）：390-419.
[8] 郑筱萸.中药新药临床研究指导原则（试行）[M].中国医药科技出版社，2002，1：364.
[9] Martincevic I，Mouzaki M. Resting Energy Expenditure of Children and Adolescents With Nonalcoholic Fatty Liver Disease [J]. JPEN J Parenter Enteral Nutr，2017，41（7）：1195-1201.
[10] 辛晟梁，徐可树.非酒精性脂肪性肝病发病机制新认识[J].临床肝胆病杂志，2017，33（8）：1581-1583.
[11] 叶咸德.老年非酒精性脂肪肝患者的血脂、脂蛋白和胱抑素C的水平变化[J].中国老年学杂志，2016，36（10）：2438-2439.
[12] 肖丽，杨玲.肠道菌群与非酒精性脂肪性肝病的关系[J].临床肝胆病杂志，2017，33（4）：774-779.
[13] Mikolasevic I，Stimac D，Racki S，et al. Relationship between non-alcoholic fatty liver disease and MIA syndrome [J]. Hemodial Int，2015，19（3）：472-481.
[14] 万艳，常剑波，白艳霞，等.血清学指标在非酒精性脂肪性肝病诊断中的意义[J].临床肝胆病杂志，2017，33（5）：963-968.
[15] 代东伶.儿童非酒精性脂肪肝最新研究动态[J].中国当代儿科杂志，2015，17（1）：107-112.
[16] Fargion S，Porzio M，Fracanzani AL. Nonalcoholic fatty liver disease and vascular disease：state-of-the-art [J]. World J Gastroenterol，2014，20（37）：13306-13324.
[17] 唐婷玉，李志军，俞李羚，等.NF-κB下游炎症因子在非肥胖OSAS患者外周血中的表达及临床意义[J].浙江医学，2017，39（11）：887-890.
[18] 孙恺，张秀萍，宋林杰，等.糖尿病合并脑缺血再灌注损伤小鼠模型制作及其炎症因子表达分析[J].中华神经医学杂志，2016，15（2）：123-129.
[19] Jung UJ，Choi MS. Obesity and its metabolic complications：the role of adipokines and the relationship between obesity，inflammation，insulin resistance，dyslipidemia and nonalcoholic fatty liver disease [J]. Int J Mol Sci，2014， 15（4）：6184-6223.
[20] 戴志毅.枫蓼肠胃康联合肠内营养混悬液治疗老年非酒精性脂肪肝合并代谢综合征的临床研究[J].现代药物与临床，2015，30（7）：809-813.
[21] Ying L，Yan F，Zhao Y，et al. （-）-Epigallocatechin-3-gallate and atorvastatin treatment down-regulates liver fibrosis-related genes in non-alcoholic fatty liver disease [J]. Clin Exp Pharmacol Physiol，2017，44（12）：1180-1191.
[22] 潘磊，崔荣岗，赵保辉，等.蛤蚧肽溶液对非酒精性脂肪肝小鼠脂代谢、肝功能及炎性因子的影响[J].陕西中医，2016，38（3）：376-379.
[23] 宋鹏，毛谅，卞晓洁，等.肝门部胆管癌术前胆汁回输联合肠内营养的疗效分析[J].中华外科杂志，2018，56（5）：367-373.